Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
Clinical trial NCT07333937 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07333937
- Sponsor
- Xijing Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-20
- Primary completion
- 2027-11-20
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.